Cargando…

Defining medication adherence in individual patients

BACKGROUND: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken. Here, we define a patient as pharmacokinetically adherent if the serum drug levels resulting from his/her pattern of medica...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, Alan, Stauffer, Melissa E, Kaufman, Anna S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494613/
https://www.ncbi.nlm.nih.gov/pubmed/26170639
http://dx.doi.org/10.2147/PPA.S86249
_version_ 1782380129493712896
author Morrison, Alan
Stauffer, Melissa E
Kaufman, Anna S
author_facet Morrison, Alan
Stauffer, Melissa E
Kaufman, Anna S
author_sort Morrison, Alan
collection PubMed
description BACKGROUND: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken. Here, we define a patient as pharmacokinetically adherent if the serum drug levels resulting from his/her pattern of medication-taking behavior remained within the therapeutic range. METHODS: We used pharmacokinetic modeling to calculate serum drug levels in patients whose patterns of dosing were recorded by a medication event monitoring system. Medication event monitoring system data were from a previously published study of seven psoriasis patients prescribed 40 mg subcutaneous adalimumab at 14-day intervals for 1 year. Daily serum concentrations of adalimumab were calculated and compared with a known therapeutic threshold. RESULTS: None of the seven patients took adalimumab precisely every 14 days. Three patients who took adalimumab at intervals of 6–26 days could be classified as pharmacokinetically adherent, because their daily adalimumab serum concentration never fell below the therapeutic threshold. The four other patients, who took adalimumab at intervals of 7–93 days, could be classified as pharmacokinetically non-adherent, because their adalimumab serum concentration fell below the therapeutic threshold on 3.5%–71.3% of days. CONCLUSION: Patients with varying patterns of adalimumab dosing could be classified as pharmacokinetically adherent or non-adherent according to whether or not their serum drug concentrations remained within the therapeutic range.
format Online
Article
Text
id pubmed-4494613
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44946132015-07-13 Defining medication adherence in individual patients Morrison, Alan Stauffer, Melissa E Kaufman, Anna S Patient Prefer Adherence Original Research BACKGROUND: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken. Here, we define a patient as pharmacokinetically adherent if the serum drug levels resulting from his/her pattern of medication-taking behavior remained within the therapeutic range. METHODS: We used pharmacokinetic modeling to calculate serum drug levels in patients whose patterns of dosing were recorded by a medication event monitoring system. Medication event monitoring system data were from a previously published study of seven psoriasis patients prescribed 40 mg subcutaneous adalimumab at 14-day intervals for 1 year. Daily serum concentrations of adalimumab were calculated and compared with a known therapeutic threshold. RESULTS: None of the seven patients took adalimumab precisely every 14 days. Three patients who took adalimumab at intervals of 6–26 days could be classified as pharmacokinetically adherent, because their daily adalimumab serum concentration never fell below the therapeutic threshold. The four other patients, who took adalimumab at intervals of 7–93 days, could be classified as pharmacokinetically non-adherent, because their adalimumab serum concentration fell below the therapeutic threshold on 3.5%–71.3% of days. CONCLUSION: Patients with varying patterns of adalimumab dosing could be classified as pharmacokinetically adherent or non-adherent according to whether or not their serum drug concentrations remained within the therapeutic range. Dove Medical Press 2015-07-01 /pmc/articles/PMC4494613/ /pubmed/26170639 http://dx.doi.org/10.2147/PPA.S86249 Text en © 2015 Morrison et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Morrison, Alan
Stauffer, Melissa E
Kaufman, Anna S
Defining medication adherence in individual patients
title Defining medication adherence in individual patients
title_full Defining medication adherence in individual patients
title_fullStr Defining medication adherence in individual patients
title_full_unstemmed Defining medication adherence in individual patients
title_short Defining medication adherence in individual patients
title_sort defining medication adherence in individual patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494613/
https://www.ncbi.nlm.nih.gov/pubmed/26170639
http://dx.doi.org/10.2147/PPA.S86249
work_keys_str_mv AT morrisonalan definingmedicationadherenceinindividualpatients
AT stauffermelissae definingmedicationadherenceinindividualpatients
AT kaufmanannas definingmedicationadherenceinindividualpatients